Cited 35 times in
Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김원주 | - |
dc.contributor.author | 이병인 | - |
dc.contributor.author | 장상현 | - |
dc.contributor.author | 정요한 | - |
dc.contributor.author | 조양제 | - |
dc.contributor.author | 허경 | - |
dc.contributor.author | 예병석 | - |
dc.date.accessioned | 2015-04-24T17:05:07Z | - |
dc.date.available | 2015-04-24T17:05:07Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0013-9580 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104731 | - |
dc.description.abstract | PURPOSE: To evaluate the long-term efficacy and tolerability of topiramate (TPM) as add-on therapy in patients with refractory partial epilepsy. METHODS: This is a retrospective, single-center, long-term observational study. Patients fulfilling the criteria of medical intractability proposed by Berg et al. were entered into the study if they were newly prescribed TPM as add-on therapy between January 2000 and June 2002. The usual starting dosage of TPM was 50 mg/day and optimal-dose adjustments were made according to individual clinical responses. Efficacy and tolerability were analyzed every year during 5-year follow-up in the "intention-to-treat (ITT) population." Retention rate was estimated by Kaplan-Meyer analysis. RESULTS: A total of 125 patients were included in the study and 107 patients (85.6%) were followed for 5 years. Retention rate was 87.2% at 1 year and 64% at 5 years. At the end of 5 years, the median seizure frequency reduction rate was 69.0% and responder rate was 43.2% in the ITT population. Cumulative seizure-free rate (SFR) was 30.4% and the terminal 1-year SFR was 12.8% in the ITT population (20.0% in completers) at 5-year follow-up. Adverse events (AEs) occurred in 39.2% of patients, including significant AEs leading to antiepileptic drug (AED) withdrawal in 14.4%. The most common AEs were anorexia (16.0%), weight loss (10.4%), and gastrointestinal symptoms (8.8%). Concomitant AEDs were reduced in 25.0% of the completers. DISCUSSION: Low-dose and slow-dose escalation of TPM in add-on therapy for patients with refractory partial epilepsy is effective and well tolerated in long-term, individualized clinical practice | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | EPILEPSIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anticonvulsants/therapeutic use* | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Electroencephalography | - |
dc.subject.MESH | Epilepsies,Partial/drugtherapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fructose/analogs & derivatives* | - |
dc.subject.MESH | Fructose/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Longitudinal Studies | - |
dc.subject.MESH | Magnetic Resonance Imaging | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Maximum Tolerated Dose | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Observation/methods | - |
dc.subject.MESH | Outcome Assessment (Health Care) | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Secondary Prevention | - |
dc.subject.MESH | Young Adult | - |
dc.title | Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학) | - |
dc.contributor.googleauthor | Yang-Je Cho | - |
dc.contributor.googleauthor | Kyoung Heo | - |
dc.contributor.googleauthor | Won-Joo Kim | - |
dc.contributor.googleauthor | Sang Hyun Jang | - |
dc.contributor.googleauthor | Yo Han Jung | - |
dc.contributor.googleauthor | Byoung Seok Ye | - |
dc.contributor.googleauthor | Dong Beom Song | - |
dc.contributor.googleauthor | Byung In Lee | - |
dc.identifier.doi | 10.1111/j.1528-1167.2009.02177.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00771 | - |
dc.contributor.localId | A02797 | - |
dc.contributor.localId | A03431 | - |
dc.contributor.localId | A03659 | - |
dc.contributor.localId | A03851 | - |
dc.contributor.localId | A04341 | - |
dc.relation.journalcode | J00793 | - |
dc.identifier.eissn | 1528-1167 | - |
dc.identifier.pmid | 19563348 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2009.02177.x/abstract | - |
dc.subject.keyword | Epilepsy | - |
dc.subject.keyword | Refractory | - |
dc.subject.keyword | Topiramate | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Tolerability | - |
dc.contributor.alternativeName | Kim, Won Joo | - |
dc.contributor.alternativeName | Lee, Byung In | - |
dc.contributor.alternativeName | Jang, Sang Hyun | - |
dc.contributor.alternativeName | Jung, Yo Han | - |
dc.contributor.alternativeName | Cho, Yang Je | - |
dc.contributor.alternativeName | Heo, Kyoung | - |
dc.contributor.affiliatedAuthor | Kim, Won Joo | - |
dc.contributor.affiliatedAuthor | Lee, Byung In | - |
dc.contributor.affiliatedAuthor | Jang, Sang Hyun | - |
dc.contributor.affiliatedAuthor | Jung, Yo Han | - |
dc.contributor.affiliatedAuthor | Cho, Yang Je | - |
dc.contributor.affiliatedAuthor | Heo, Kyoung | - |
dc.citation.volume | 50 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1910 | - |
dc.citation.endPage | 1919 | - |
dc.identifier.bibliographicCitation | EPILEPSIA, Vol.50(8) : 1910-1919, 2009 | - |
dc.identifier.rimsid | 40163 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.